Komplexní servis pod jednou střechou
Farmaceutický průmysl v České republice z velké části ovládají zahraniční vlastníci. Farmaceutické společnosti se pohybují v prostředí nesmírně přísné a komplexní regulace: Státní ústav pro kontrolu léčiv reguluje všechny aspekty tohoto podnikání – od tvorby cen po balení, od klinických zkoušek po reklamu.
Odborníci PwC na farmaceutický průmysl patří k předním specialistům na tento obor v zemi a dokáží vám dobře poradit s daňovými, právními a regulačními otázkami tohoto odvětví.
US Tax Reform will impact both US and non-US Pharma companies. This PwC presentation examines some of the main provisions.
Pharmaceutical and life sciences CEOs will have to balance the promise of new products and better medicines with a more consumer-centric marketplace that demands real-time results, and where new competitors are staking a claim. Finding talent or re-skilling their workforce will be a key to success, but the top brass may have to do more to attract a diversified talent pool.
Overcoming challenges and unlocking value from data to shape the future of R&D using data and analytics.
Wearable technology has taken the world by storm over the past number of years. Members of the public have been liberated, finally able to take control over their health, wellbeing and lifestyle. More so now than ever, lifestyle has become a major factor in the success of many sectors
Controlled drugs are heavily regulated across the healthcare sector. They are drugs controlled under the Misuse of Drugs regulations 2001, that are open to abuse, misuse, illegal activity or can cause harm, i.e. morphine. Why is regulation important?
An analysis for pharmaceutical, biotechnology, medical device, diagnostic and healthcare companies and healthcare institutes.
PwC’s insight on how to apply IFRS in common pharmaceuticals and life sciences transactions, including guidance on the new revenue standard, IFRS 15.
The solutions presented in this publication are meant to provide a framework for determining the appropriate accounting answer for general situations.
The New Health Economy is inspiring fresh ways to manage data, place a value on medical treatments, and deal with empowered patients.
The solutions presented in this publication are meant to provide a framework for determining the appropriate accounting answer for general situations.
An analysis by PwC industry specialists for pharmaceutical, biotechnology, medical device, diagnostic and healthcare companies and healthcare institutes.
In this issue, we cover healthcare market trends and challenges, M&A trends, and regulatory developments in the Asia-Pacific region.
In this issue, we cover healthcare market trends and challenges, M&A trends, and regulatory developments in the Asia-Pacific region.
PwC's Global Health Industries network is pleased to present you with its 13th issue of the Asia-Pacific Health Industries Newsletter.
PwC's Global Health Industries network is pleased to present you with its 12th issue of the Asia-Pacific Health Industries Newsletter.
In this edition we highlight recent developments in Asia and Australia including changes in China's compliance and pricing environment, pharmaceutical deals in South Korea and India, digital health, Big Data, and tax developments in Australia, Hong Kong, China and Singapore.
PwC researches pharma relationship performance in large scale clinical outsourcing and lessons from R&D outsourcing in other hi-tech industries.
PwC's Pharma 2020 series reports look into the future of the Pharmaceuticals and Life Sciences’ value chain, and they include an analysis of the strategies needed to compete successfully in the future.
PwC's report discusses how pharma companies must develop different supply chain models for different product types and patient segments, use their supply chains for market differentiation and see the role information plays to drive the flow of products and services.
The fifth report in the series, it focusses on the opportunities and challenges from a tax perspective. It discusses how the political, economic, scientific and social trends currently shaping the commercial environment, together with the development of new, more collaborative business models, will exert increasing pressure on effective tax rates within the industry. It also shows how companies can adapt their strategies to support the provision of outcomes-based healthcare and remain competitive.
Pharma 2020: Challenging business models - Which path will you take?
This paper discusses how the industry is no longer being rewarded for incremental innovation, me-too products and selling the most pills. Companies need to add value to patients, and offer a package of products and health services that the market is willing to pay a premium for.
Few tax issues are more fact-intensive than determining the tax consequences to the payor of payments made under a settlement agreement with a governmental body when the agreement is silent as to the nature of the payments. In a legal advice memorandum, the IRS Office of Chief Counsel shed some light on the factors it thinks are important in such a situation. Whenever possible, of course, the taxpayer should seek to negotiate settlement agreement terms that would support the desired tax treatment.
Pharma 2020: Virtual R&D explores how pharma companies could dramatically improve the R&D productivity. It contents that by 2020 the R&D process may be shortened by two-thirds, success rates may dramatically increase, and clinical trial costs could be cut substantially. New computer based technologies will create a greater understanding of the biology of disease and the evolution of ‘Virtual man’ to enable researchers to predict the effects of new drug candidates before they enter human beings.
But Pharma 2020: The Vision - Which Path Will You Take? indicates that the current pharmaceutical industry business model is both economically unsustainable and operationally incapable of acting quickly enough to produce the types of innovative treatments demanded by global markets. In order to make the most of these future growth opportunities, the industry must fundamentally change the way it operates.
*K dispozici v anglických originálech
Bořivoj Líbal
Ondřej Dostál
